Biogen (BIIB) Long-Term Investments (2009 - 2026)

Biogen has reported Long-Term Investments for 17 years, with the latest figure at $465.6 million in Q1 2026.

• On a quarterly basis, Long-Term Investments changed N/A year-over-year to $465.6 million in Q1 2026; TTM through Mar 2026 was $465.6 million, a N/A change from a year earlier, with the FY2025 full-year figure at $431.9 million, changed N/A from the prior year.
• Long-Term Investments was $465.6 million for Q1 2026 at Biogen, up from $431.9 million in the prior quarter.
• The five-year high for Long-Term Investments was $1.2 billion in Q2 2023, with the low at $100000.0 in Q3 2023.
• Average Long-Term Investments over 4 years is $750.5 million, with a median of $860.3 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments advanced 21.86% in 2022, then tumbled 99.99% in 2023.
• Over 4 years, Long-Term Investments stood at $705.7 million in 2022, then tumbled by 99.99% to $100000.0 in 2023, then surged by 431800.0% to $431.9 million in 2025, then increased by 7.8% to $465.6 million in 2026.
• The last three Long-Term Investments figures came in at $465.6 million (Q1 2026), $431.9 million (Q4 2025), and $100000.0 (Q3 2023), per Business Quant data.